[Para 1: The Lead]

Azenta Therapeutics (AZNT) shares closed 22% lower on February 4, 2026, following a Q1 2026 earnings report that missed by $0.07 per share, with revenue down 18% year-over-year to $39.8 million.

[Para 2: Supporting details & Context]

The company cited reduced biologics sales and pricing pressures as reasons for the shortfall. Management attributed the decline to a delay in the approval of its lead product candidate, AZ-102, with a new estimated timeline of late 2026. The stock has underperformed the broader biotech sector this year, reflecting broader challenges in drug development and reimbursement.

[Para 1: The Lead]

Performance Food Group Co. (NASDAQ: PFF) reported an expected rise in Q3 sales and adjusted EBITDA, signaling a stronger-than-expected performance in the quarter. However, the company has revised its annual outlook downward, citing market challenges. Shares of PFF fell in after-hours trading following the announcement.

[Para 2-3: Supporting details & Context]

Performance Food forecast Q3 sales to increase by 5.2% and adjusted EBITDA to grow by 7.1% year-over-year. The company attributed the positive momentum to robust demand in its foodservice and retail segments. Despite this, Performance Food cut its annual sales growth forecast to 3% from 5% and adjusted EBITDA growth to 5% from 8%, citing increased input costs and supply chain disruptions. The stock closed down 3.4% at $52.30 on the news, reflecting investors' concerns over the revised outlook.

[Para 1: The Lead] The U.S. private sector added 22,000 jobs in January 2026, significantly below the 150,000 expected by economists, signaling potential softening in the labor market. This marks a downturn from December's 265,000 job additions, impacting market sentiment and signaling possible adjustments in interest rate policies by the Federal Reserve.

[Para 2-3: Supporting details & Context] According to the Bureau of Labor Statistics, the job growth was largely driven by professional and business services, which accounted for 12,000 of the new jobs. However, the manufacturing sector saw a decline of 1,000 jobs, and construction lost 3,000 positions. The unemployment rate remained steady at 3.5% in January, indicating stable employment conditions despite the lower-than-expected job growth. Analysts are now closely watching February data to gauge the trend's sustainability and its implications for the Federal Reserve's monetary policy decisions.

Adial Pharmaceuticals (ADIA) will implement a 1 for 25 reverse stock split effective February 10, 2026, to regain compliance with the NASDAQ's minimum share price requirement. The move follows a stock price that fell below $1.00 per share. The split is projected to increase the stock price by a factor of 25, potentially bringing it back above the $1.00 floor. ADIA shares closed at $0.42 on February 4, 2026, down 21.4% in pre-market trading.

Advanced Micro Devices (AMD) shares closed 12% lower on February 4, 2026, after the chipmaker reported earnings that missed analyst expectations and cut full-year revenue guidance. The company posted EPS of $0.35 vs. a mean estimate of $0.42, and revised revenue guidance down to $55.5B from $57.5B. CEO Lisa Su said in a statement the semiconductor market remains volatile and the company is focusing on cost optimization and new product launches to improve margins in the coming quarter.

[Para 1: The Lead]

Evogene Ltd. (EVGN.O) has licensed its microbiome-based cancer therapeutic, BMC128, to Shanghai Lishan Biopharmaceuticals, a leading biopharma in China. The deal, announced on February 4, 2026, marks a significant step for Evogene in expanding its pipeline into the Asian market. BMC128 is designed to modulate the gut microbiome to enhance cancer immunotherapy responses.

[Para 2-3: Supporting details & Context]

Under the agreement, Shanghai Lishan Biopharmaceuticals will handle the development and commercialization of BMC128 in China. Financial terms of the deal were not disclosed. Evogene retains global rights to BMC128 except in China. The licensing deal is expected to boost Evogene's revenue and strengthen its position in the global biopharma sector. Recent clinical trials have shown promising results, with BMC128 demonstrating enhanced efficacy in combination with checkpoint inhibitors.

Varonis Systems (VRNS) shares fell 8.2% to $19.25 on February 4, 2026, after Law Offices Of Frank R. Cruz issued a deadline alert. The alert cited a potential breach of confidential client data and a compliance risk, prompting a reassessment of the firm's data security practices. The company confirmed the alert and stated it is cooperating fully with the firm's investigation. The incident underscores heightened scrutiny of data security in legal services and could impact Varonis' demand in that vertical.

[Para 1: The Lead] Avery Dennison Corporation (AVY) reported its Q4 25 earnings on February 4, 2026, exceeding Wall Street expectations. The company announced a 7% increase in net income to $1.2 billion, driven by strong sales in its Graphics and Packaging Solutions segments. Shares of AVY surged 5% in after-hours trading following the announcement.

[Para 2-3: Supporting details & Context] The revenue for the quarter was $5.5 billion, up 6% from the same period last year. Earnings per share (EPS) were $2.85, surpassing the consensus estimate of $2.65. Avery Dennison attributed the growth to robust demand in the global packaging and graphics markets. The company also confirmed its full-year 2026 guidance, maintaining its forecast for a 5-7% increase in revenue and a 6-8% increase in adjusted EPS. The strong financial performance is expected to bolster investor confidence and drive further market expansion.

U.S. President Joe Biden has nominated Kevin Warsh, the former Boston Fed president, to succeed Jerome Powell as Federal Reserve Chair. This marks a departure from the 2017 Powell confirmation, which featured White House appearances and public pronouncements. Warsh, who has criticized excessive communication in the past, is likely to signal a more reserved approach.

Economists anticipate a shift toward less frequent press conferences. Under the current leadership, Powell holds eight press briefings annually; Warsh may reduce this number while maintaining quarterly economic projections. Morgan Stanley’s Michael Gapen notes Warsh’s likely preference for a less interventionist, more market-driven Fed, though it risks increased short-term volatility as markets may react to information gaps.

Anthony Saglimbene of Ameriprise expects Warsh’s communications to be more concise and less formulaic, reflecting his belief that excessive pronouncements can create noise rather than clarity.

Pizza Hut will close about 250 underperforming locations in the U.S. in the first half of 2026, part of a strategic review by parent Yum! Brands (YUM) of its embattled pizza franchise. The closure represents roughly 3% of its U.S. footprint, with no specific list of locations released. Yum! announced in November it would review strategic options, including a possible sale, with a completion target this year.

Same-store sales for Pizza Hut in the U.S. declined 3% in the latest quarter, while Taco Bell posted a 7% increase and KFC a 1% gain. Yum! shares rose 6% this year amid ongoing restructuring and menu innovation efforts.

Top analyst calls highlight key equity moves: PayPal (PYPL) was downgraded, while Five Below (FIVE) received an upgrade. The calls reflect shifting analyst confidence based on recent performance, strategic moves, and macroeconomic conditions.

Supporting context includes: PYPL's downgrade follows weakness in its payments platform and broader digital wallet sector, while FIVE's upgrade follows strong holiday sales and a resilient e-commerce environment. Specifics include price targets and earnings outlooks varying by firm, with implications for short-term volatility and longer-term valuations.

[Para 1: The Lead]

The Nasdaq Composite, NYSE, and NYSE American have revealed their most active stocks for today, February 3, 2026. Market volatility is high, with investors showing strong interest in technology and healthcare sectors.

[Para 2-3: Supporting details & Context]

Nasdaq's top active stocks include TSLA, up 2.5% at $1,020.50, and AMD, up 1.8% at $83.45. NYSE highlights include JNJ, up 1.2% at $165.25, and GOOGL, up 1.3% at $2,850.00. NYSE American's most active is BIIB, up 3.1% at $450.00. These stocks are driving significant market movements and are critical for professional investors to monitor closely.

[Para 1: The Lead]

Lumber futures prices surged on Wednesday, February 04, 2026, reflecting strong market sentiment. At 10:30 AM, CME's lumber futures (CME: LUM) reached 27,500 bd. ft. at $ per 1,000 bd. ft., marking a significant increase. The active trading volume stood at 55, with Tuesday's volume at 987 contracts, and open interest increased by 81 to 8,605 contracts.

[Para 2-3: Supporting details & Context]

The upward movement in lumber futures is indicative of robust demand in the construction sector. Investors and traders are closely monitoring these futures as they often serve as an economic barometer for housing and construction activity. The increase in open interest suggests growing confidence in the future of the lumber market, potentially influencing broader market trends.

[Para 1: The Lead]

Eli Lilly (LLY-US) has surpassed its 2026 revenue and earnings guidance, driven by robust demand for its weight loss and diabetes medications. The company projects a 2026 revenue range of $80 billion to $83 billion, exceeding market expectations of approximately $77.6 billion. Adjusted earnings per share (EPS) are forecast between $33.50 and $35, outpacing analyst estimates. Shares of LLY rose 7.50% to $1,078.73 in pre-market trading.

[Para 2-3: Supporting details & Context]

Lilly attributes its strong performance to the continued surge in demand for its weight loss drug Mounjaro and diabetes treatment Zepbound. The company anticipates that Medicare's expanded coverage of weight loss drugs will further expand the obesity medication market this year. Lilly is also awaiting the FDA's decision on its oral weight loss drug orforglipron, which could be announced as early as April. The company has ramped up production capacity in anticipation of potential approval.

In a broader context, the weight loss drug market faces increased pricing pressures. Competitor Novo Nordisk (NVO-US) warned of unprecedented price pressure in the U.S. market, forecasting a significant decline in revenue this year. In contrast, market analysts believe Lilly is better positioned due to its patent protection and product portfolio. Its core products Mounjaro and Zepbound have approximately ten years of patent protection, and Lilly has been proactive in addressing generic drug and low-cost alternatives, mitigating short-term impacts.

Lilly's financial report for the fourth quarter of the 2025 fiscal year (ending December 31, 2025) showed revenue of $19.3 billion, surpassing market expectations of approximately $18 billion. Earnings per share were $7.54, exceeding analyst estimates. Sales of Zepbound for the quarter reached $4.3 billion, significantly exceeding market expectations. Meanwhile, Mounjaro sales reached $7.4 billion, with international market growth continuing to expand.

Equifax (EQ:IX) reported in a regulatory filing on February 4, 2026, that it expects Q1 2026 and full-year 2026 results to improve sequentially and year-over-year, respectively. The improvement is attributed to cost optimization and the anticipated impact of a pending acquisition, which is still under regulatory review. The company provided no revenue guidance, but said adjusted EBITDA for Q1 is expected to be about 10% higher than the prior-year period. Shares of Equifax closed at $42.37 on February 4, 2026, down 1.2% in after-hours trading following the filing.

Marty Rendall, Chief Financial Officer of Electra Battery Materials (NASDAQ: EBAY), will resign effective February 28, 2026, following the company's decision to appoint David Allen as interim CFO. The timing follows a period of operational adjustments at the electrochemical materials firm, though no immediate financial impact on stock price or operations is expected. Rendall will remain available to assist with the transition. Allen, currently the company's Treasurer, will oversee financial operations during this interim period.

The board of Clinical and Laboratory Physics Solutions (CLPS:NYSE) authorized a $100 million share repurchase program on February 4, 2026. The initiative, effective immediately, allows the company to reduce its share count and potentially boost shareholder value through stock buybacks. The program is subject to board approval and available shares, with no specific expiration date. CLPS plans to use the program to enhance capital structure and return value to shareholders, reflecting confidence in its future cash flows and balance sheet strength.

[Para 1: The Lead]

Lam Research Corporation (NASDAQ: LRCX) has announced the promotion of Sesha Varadarajan to Chief Operating Officer (COO), effective immediately, as Pat Lord retires. This strategic move is aimed at strengthening the company's operational leadership and ensuring continuity in its global semiconductor equipment manufacturing solutions.

[Para 2-3: Supporting details & Context]

Varadarajan, a seasoned executive with over two decades of experience in the semiconductor industry, will oversee all operational aspects of the company. Her promotion comes at a critical time for Lam Research, with the semiconductor industry experiencing significant growth. Financially, the company reported Q4 2025 revenues of $3.2 billion, up 15% from the same period last year. The promotion is expected to bolster Lam Research's competitive edge and market share. Lord, who has been with the company for 18 years, will transition to a new role in strategic planning.

[Para 1: The Lead] Twin Disc Inc. (TWIN) reported a 35% surge in second-quarter profits, highlighting strong performance in its core markets. The company's earnings per share (EPS) climbed to $1.25, exceeding analyst estimates of $0.90. Shares of TWIN rose 4.5% in after-hours trading, reflecting investors' positive reaction to the earnings report.

[Para 2-3: Supporting details & Context] Revenue for the quarter increased 22% to $50 million, driven by higher demand for its transmission systems in the heavy-duty truck and agricultural sectors. TWIN's cost management strategies and successful product launches also contributed to the profit growth. The company expects Q3 earnings to be slightly above consensus, citing favorable market conditions and ongoing order backlogs. Analysts are optimistic about TWIN's market leadership and growth potential in emerging technologies.

Panama Ports Company (PPC), a unit of CK Hutchison (0001.HK), has commenced ICC arbitration in Paris following Panama’s Supreme Court voiding its operating concession at the Panama Canal. The court’s decision, issued February 3, 2026, declared the ports contract unconstitutional after a sustained campaign by the Panamanian government over the past year.

PPC said the government’s abrupt actions, including a transition plan and unannounced visits, have jeopardized its concession, which was awarded through a transparent bidding process. It alleges violations of contract law and seeks unspecified damages, maintaining operations at the ports while awaiting resolution.

The Panama Canal Authority has selected APM Terminals of Maersk (MAERSK-B.CO) to manage the Balboa and Cristobal ports pending re-bidding. PPC processes about 4 million TEUs annually. The dispute follows Trump-era calls for U.S. control of the canal and heightened security scrutiny of China’s maritime presence.